Hepatitis B virus resistance to antivirals: clinical implications and management. (Q35621690)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

Hepatitis B virus resistance to antivirals: clinical implications and management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

author name string

Fabien Zoulim

series ordinal

1

1 reference

9 August 2017

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

volume

39 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

S133-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

17 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Hepatitis B viral resistance: mechanisms and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Combination therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900312-X

7 January 2021

10.1016/S0168-8278(03)00312-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708691%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference